Drug Information Association Logo
Corporate Tagline

Two-part Series: Impact of the New European Pharmacovigilance Legislation on International Companies

| Online

« Back to Listing

Overview 

Continuing Education credit or Certificate Program units are not available for the archived offering.


In July 2012, new pharmacovigilance legislation became effective across the EU as a result of changes set out in:

Regulation (EU) No1235/2010
Directive 2010/84/EU

The legislation is underpinned by an EC Implementing Measures Regulation and a series of modules on Good Pharmacovigilance Practice. Are you confident your pharmacovigilance operations will meet the EU’s latest expectations for compliance? Do you understand the processes needed to perform adequate risk assessment?

Not knowing which systems and processes you must have in place for the new European pharmacovigilance requirements could have significant consequences for your product. Be sure you have the techniques you’ll need to work to EU standards and have implemented regulatory requirements for signaling and risk management.

This two-part webinar series is designed to give pharmaceutical and biologic companies operating in the EU an introduction to the new European pharmacovigilance requirements.


This archived webinar is available through July 19, 2013.

Featured Topics 

Part 1:

  • EU regulatory framework
  • Timeframe for implementation of the new legislation
  • GVP modules and implementing measures
  • PV System Master File (PSMF)
  • Audit and inspection
  • ADR reporting

Part 2:

  • Periodic Safety Update Reports
  • Signal management
  • Risk Management Plans: risk assessment and risk minimization
  • Implications for international harmonization topics

Who Should Attend 

Professionals involved in:

  • Drug safety and pharmacovigilance
  • Regulatory affairs
  • Clinical development
  • Executives (including C-Level) with an legal responsibility for drug safety

Learning Objectives 

At the conclusion of this webinar, participants should be able to:

  • Discuss the new EU regulatory requirements for drug safety
  • Describe how to process adverse events to meet EU requirements
  • Explain what to expect in a European PV inspection

Contact Information 

For information about archived webinars:
Carolyn Callahan
Phone +1.215.442.6194
Fax +1-215.442.6199
Carolyn.Callahan@diahome.org

Technical Requirements 

Click here for minimum system requirements.

Presenter(s) 

Previous Next

Agenda  

Day 1 Friday, July 20, 2012

  • 7:00AM - 11:59PM

    Two-part Series: Impact of the New European Pharmacovigilance Legislation on International Companies

    Speaker(s):

    • Impact of the New European Pharmacovigilance Legislation on International Companies
      Joanna Faith Haas, MD,MSc,FACPM,FISPE
      Founding Partner
      Haas and Partners, United States
    • EU GVP Modules V, VII, VIII, IX
      Steve Jolley, MA
      Principal
      SJ Pharma Consulting, United States

Registration Fees 

Other Fees

Government (Full Time) Individual
$225.00
Charitable Nonprofit/Academia Individual
$275.00
Group Site
$999.00
Group Plus
$1195.00

Member

Member Individual
$350.00

Non-Member

NonMember Individual
$395.00
Register Online

Unless otherwise disclosed, the statements made by speakers represent their own opinions and not necessarily those of the organization they represent, or that of the Drug Information Association. Speakers, agenda and CE information are subject to change without notice. Recording of any DIA educational material in any type of media is prohibited without prior written consent from DIA.

« Back to Listing Back To Top